Aethlon Medical Inc. (AEMD) - Form 8-K Summary
Business Context and Reporting Period
Aethlon Medical, Inc., a Nevada corporation headquartered in San Diego, California, filed this Current Report on Form 8-K on August 13, 2025. The filing serves to disclose the Company's financial results for the quarter ended June 30, 2025, pursuant to Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the body text. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not detailed in the provided text. The report notes that the information in Item 7.01 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 13, 2025) for specific Q2 2025 financial figures.
- Verify the Company's cash position and burn rate given the lack of explicit liquidity data in the 8-K body.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the referenced press release.
- Check for any new debt covenants or financing activities disclosed in the full press release.